On June 1, 2026, at the annual meeting of the American Society of Clinical Oncology (ASCO), Professor Zhao Hongyun, Director of the Phase I Clinical Ward at Sun Yat-sen University Cancer Center, delivered an oral presentation on behalf of investigators from all participating clinical trial sites. She unveiled Phase I clinical data of DXC006, the world’s first-in-class CD56-targeted ADC developed by Hangzhou DAC Biotech, for the treatment of solid tumors including small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and neuroendocrine carcinoma.

As of April 1, 2026, a total of 100 patients have been enrolled, including 66 with SCLC, 20 with neuroendocrine tumors, and 14 with NSCLC. Approximately 39% of the patients had brain metastases. In the SCLC cohort, DXC006 demonstrated remarkable antitumor activity. Among second-line SCLC patients, DXC006 monotherapy achieved an objective response rate (ORR) of 75.0% and a disease control rate (DCR) of 100.0%. In heavily pretreated later-line SCLC patients, the ORR was 59.3% and DCR was 89.8%.

In heavily pretreated patients with adenocarcinoma and neuroendocrine tumors, the majority achieved sustained tumor regression. Specifically, DXC006 monotherapy demonstrated an ORR of 45.5% and a DCR of 72.7% in adenocarcinoma, and an ORR of 21.1% and DCR of 63.2% in later-line neuroendocrine tumors.

DXC006 demonstrates a manageable safety profile and adequate tolerability. Among the 100 solid tumor patients, the incidence of grade ≥3 treatment-related adverse events (TRAEs) was 27%, including 21% hematologic AEs and 4% gastrointestinal AEs. 

Professor Zhao Hongyun said in a media interview: 

“DXC006 has demonstrated excellent safety in Phase I clinical studies and shown significant clinical benefits in patients with extensive-stage small cell lung cancer, offering a new treatment option for this patient population with high unmet medical needs. Building on the solid foundation and strong development starting point established in the Phase I trial, DXC006 has now initiated two Phase II clinical trials for small cell lung cancer. We look forward to accelerating the global clinical translation of this innovative ADC, transforming scientific value into tangible patient benefits, and bringing hope to lung cancer patients worldwide.”

Dr. Robert Zhao, Founder, Chairman, and CEO of Hangzhou DAC, stated:

“The safety and efficacy data of DXC006 in SCLC reinforce our confidence to accelerate clinical development. We plan to initiate the Phase III registrational trial for DXC006 in early 2027. In addition to the monotherapy studies, Phase II trials of DXC006 in combination with PD-1 inhibitors or platinum-based chemotherapy for first-line and first-line maintenance treatment of SCLC are underway. 

Our CrossConju™ site-specific conjugation technology and Topo1 payload-linker platform have been successfully applied to multiple proprietary ADC candidates, with validation from clinical trials. We are fully committed to advancing our proprietary pipeline, focusing on unmet medical needs, and continuously bringing more high-quality treatment options to cancer patients worldwide.”

About DXC006

DXC006 is a recombinant humanized anti-CD56 monoclonal antibody-CPT113 conjugate. It utilizes a humanized, high-affinity anti-CD56 antibody conjugated via a chemical bridge site-specific conjugation technology (CrossConju™) to a highly potent camptothecin analog CPT116 at the Fab region. DXC006 remains highly stable in systemic circulation, is selectively cleaved within the tumor microenvironment, and releases cytotoxic payloads that kill both target-expressing tumor cells and neighboring bystander tumor cells.

About the CPT113

The CPT113 platform is a next-generation payload-linker system developed by Hangzhou DAC, combining a camptothecin analog CPT116 and CrossConjuanalog CPT116 t-generation payload-linker system developed ved within the tumor microenvironment, and releases cytotoxic payloads that kill both target-exprcMET bispecific ADC JNJ-95437446, while Whitehawk Therapeutics unveiled three ADC assets HWK-007, HWK-016 and HWK-206. All products were developed using DAC’s CPT113 platform and CrossConju™ technology.